



Infographic: Laser in Glaucoma and Ocular Hypertension Trial (LiGHT)

Nawara Behzad¹ · Yen Ning Mau¹ · Rashmi G. Mathew¹ · Christin Henein 10¹

Received: 13 December 2020 / Revised: 16 December 2020 / Accepted: 21 January 2021 / Published online: 10 May 2021 © The Author(s), under exclusive licence to The Royal College of Ophthalmologists 2021, corrected publication 2021




Fig. 1 The Laser in Glaucoma and ocular Hypertension Trial (LiGHT) showed that at 3 years follow up initial selective laser trabeculoplasty followed by conventional medical therapy as required to reach target IOP was more cost effective than medical therapy alone for patients with ocular hypertension or primary open angle glaucoma. *IOP* intraocular pressure, *OHT* ocular hypertension, *POAG* primary

open angle glaucoma, *SLT* selective laser trabeculoplasty, *VA* visual acuity, *VF* visual field. Reference to original study: Gazzard G, Konstantakopoulou E, Garway-Heath D, Garg A, Vickerstaff V, Hunter R, et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet. 2019;393(10180):1505–16.

Compliance with ethical standards

Conflict of interest The authors declare no competing interests.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

[☐] Christin Henein c.henein@ucl.ac.uk

UCL Institute of Ophthalmology, London, UK